Mountain Valley MD announced it has filed a novel cancer adjuvant patent related to breast cancer, metastatic melanoma, and lung carcinoma. Mountain Valley MD is a biotech and life sciences company implementing patented Quicksome oral drug formulation and delivery technologies and its Quicksol solubilization technology. MVMD's core technology applied to the Ivermectin drug is unique in that it only uses excipients (substances formulated alongside the active ingredient) that are currently approved by the FDA. MVMD's cancer patent targets direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens. The cancer-specific CRO's will run three separate pre-clinical trials: triple-negative breast cancer; metastatic melanoma; Lewis Lung Carcinoma as a proxy for non-small cell lung carcinoma. MVMD currently own patents on the only form of ivermectin that can be directly injected into a tumor or provided through more bio-available forms such as intravenously. Ivermectin has exhibited powerful antitumor effects in a variety of cancer cells and promotes programmed cancer cell death, including apoptosis, autophagy, and necrosis. Ivermectin has also been shown to inhibit tumor stem cells and reverse multidrug resistance. MVMD filed its cancer adjuvant patent, Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies for its solubilized ivermectin (Ivectosol).